SERPINA4 and metabolic dysfunction-associated steatotic liver disease: Fang et al. reported significantly elevated serum kallistatin levels in hyperlipidemic subjects and NAFLD patients compared to normal people, which may be partially attributed to the antagonistic effect of elevated free fatty acids on the inhibitory action of thyroid hormone T3 on kallistatin expression (20).